Physician profile
Samir Gupta
NPI 1861457178
$5,530.89
in general payments reported to CMS, 2019-2025
26 companies · $804 in 2025
The $804 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,892 · 2020: $1,004 · 2021: $906 · 2022: $423 · 2023: $297 · 2024: $204 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.69 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $700.80 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Allergan, INC. | $651.66 | 2019-2020 | |
| Lundbeck LLC | $581.40 | 2019-2025 | Abilify Maintena |
| Abbvie INC. | $554.69 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $502.16 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $402.73 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $378.08 | 2020-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $313.87 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $266.62 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $201.60 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Bausch Health US, LLC | $154.56 | 2019-2021 | |
| Shire North American Group INC | $143.44 | 2019 | |
| Neurocrine Biosciences, INC. | $131.25 | 2019-2024 | Ingrezza |
| Corium, LLC | $115.60 | 2021-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $81.44 | 2024-2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $74.32 | 2021 | |
| Adlon Therapeutics L.P. | $61.11 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $59.20 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.38 | 2025 | Caplyta |
| Tris Pharma INC | $23.31 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.64 | 2021 | |
| Pfizer INC. | $16.35 | 2022 | |
| Neos Therapeutics, Lp | $14.09 | 2019 | |
| Axsome Therapeutics, INC. | $13.49 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $13.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.